preponderance of females (84%), and mean (range) age of 40.5 (9-86) years. Omalizumab was 55 prescribed for asthma in most (80%) patients. A prior anaphylactic event unrelated to omalizumab was 56 documented in 43% (n=37) of patients who provided an anaphylaxis history. 57
The most common symptoms reported during omalizumab-associated anaphylaxis involved the 58 respiratory tract (95%; 91/96). The majority of patients also reported experiencing 59 cutaneous/angioedema symptoms (Table EI available (~70%) cases of anaphylaxis occurred within the first 3 doses, while in the X-PAND study, 1 this number 74 was 40% (Fig. 1A) . All three studies suggest that a significant fraction of patients with omalizumab-75 associated anaphylaxis have a prior history of anaphylaxis unrelated to omalizumab (Fig. 1B) and that 76 more than half of the anaphylactic events happened within 60 minutes of omalizumab administration 77
This dataset represents the largest number of adjudicated cases of anaphylaxis associated with 79 omalizumab, and is about 3 times the number of adjudicated anaphylaxis cases reported in our initial 80 study. 1 These results suggest that a specific subpopulation of patients, ie, those with a prior history of 81 anaphylaxis unrelated to omalizumab use, may be particularly prone to developing anaphylaxis with 82 omalizumab administration. It is critical to note that this observation was unexpected. We are not aware 83 of any prior report identifying risk factors for anaphylaxis against a specific drug or biologic agent, 84 except when the risk factor includes IgE sensitization to a substance that cross reacts with the drug or 85 biologic agent. Patients who have had episodes of anaphylaxis, particularly those in whom a causative 86 agent can be identified (eg, with food or bee venom), are known to have a higher risk of recurrent 87 episodes of anaphylaxis, 3-5 but the mechanism by which prior anaphylaxis unrelated to omalizumab 88 results in omalizumab-associated anaphylaxis is perplexing, especially because most omalizumab-89 associated anaphylactic events do not appear to be IgE mediated (eg, no IgE anti-omalizumab antibodies 90 have been detected in omalizumab-associated anaphylaxis in the limited number of patients analyzed). Final analysis (n = 96)
